

**From:** [Houck, Christina M](#)  
**To:** [KSmyth@paxvax.com](mailto:KSmyth@paxvax.com)  
**Cc:** [Hoffman, Kelsy](#)  
**Subject:** Proprietary Name Review-STN 125597  
**Date:** Monday, December 21, 2015 2:16:04 PM

---

Dear Mr. Smyth,

We have reviewed the proprietary name VAXCHORA submitted on October 16, 2015, to your biologics license application (BLA) for Cholera Vaccine, Live, Oral.

In consultation with CBER's Advertising and Promotional Labeling Branch (APLB) we conclude that under the Federal Food, Drug, and Cosmetic Act and applicable regulations, your proposed proprietary name, VAXCHORA is acceptable.

Regards,  
Christina

Christina Houck  
Regulatory Project Manager  
Food and Drug Administration  
Center for Biologics Evaluation and Research  
Office of Vaccines Research and Review  
10903 New Hampshire Avenue  
White Oak Bldg. 71  
Silver Spring, MD 20993  
Tel: [301-796-2640](tel:301-796-2640)  
Fax: [301-827-3532](tel:301-827-3532)  
Email: [christina.houck@fda.hhs.gov](mailto:christina.houck@fda.hhs.gov)

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.